The increasing prevalence of multidrug-resistant bacterial infections places medical microbiology laboratories at the frontline of therapeutic decision-making. In this context, bacteriophage therapy is re-emerging as a targeted anti-infective strategy that directly integrates laboratory expertise into clinical management. This systematized literature review synthesizes current biological and clinical evidence on phage therapy, with a specific focus on its relevance for medical microbiologists. Particular attention is given to the phagogram as a diagnostic tool analogous to the antibiogram, enabling strain-specific selection of therapeutic bacteriophages. Technical, organizational, and regulatory challenges associated with implementing phage therapy within routine laboratory work- flows are discussed. Overall, phage therapy represents an emerging extension of precision microbiology, reinforcing the central role of the clinical laboratory in personalized anti-infective strategies.

Keywords: Phage Therapy; Medical Microbiology; Phagogram; Antimicrobial Resistance

1. Murray CJ., et al. “Global burden of bacterial antimicrobial resistance in 2019”. Lancet 10325 (2022): 629-655.
2. World Health Organization. “Antimicrobial resistance”. Geneva: WHO (2023).
3. Theuretzbacher U., et al. “The global antibacterial pipeline”. Nature Reviews Microbiology 5 (2020): 275-285.
4. Ansaldi M., et al. “Applications antibactériennes des bacteriophages”. Virologie 1 (2020): 23-36.
5. Górski A., et al. “Phage therapy: current status and perspectives”. Medicinal Research Reviews 1 (2020): 459-463.
6. Kortright KE., et al. “Phage therapy for multidrug-resistant infections”. Journal of Clinical Investigation 5 (2025): e187996.
7. Pires DP., et al. “Updates on phage therapy applications”. Frontiers in Microbiology (2025).
8. Pirnay JP., et al. “The Magistral Phage”. Viruses 2 (2018): 64.
9. Torres-Barceló C. “The evolutionary rationale for phages as complements of antibiotics”. Trends in Microbiology 4 (2016): 249-256.
10. Abedon ST. “Phage biology and applications”. Advances in Applied Microbiology (2019).
11. Sundararajan A., et al. “Phage-antibiotic synergy in multidrug-resistant bacterial infections”. Scientific Reports (2025).
12. Manohar P., et al. “Phage-mediated resensitization of antibiotic-resistant bacteria”. Scientific Reports (2025).
13. Jault P., et al. “Efficacy and tolerability of a bacteriophage cocktail to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomized, controlled, double-blind phase 1/2 trial”. Lancet Infectious Diseases 1 (2019): 35-45.
14. Dedrick RM., et al. “Inhaled phage therapy for chronic respiratory infections”. Natural Medicine (2025).
15. Schooley RT., et al. “Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection”. Antimicrobial Agents and Chemotherapy 10 (2017): e00954-17.
16. Shabbir MA., et al. “Systematic review of phage therapy in multidrug-resistant infections”. (2025).
17. Hagens S and Loessner MJ. “Application of bacteriophages for detection and control of foodborne pathogens”. Current Pharmaceutical Biotechnology 11 (2010): 58-68.
18. Pirnay JP., et al. “Clinical applications of bacteriophage therapy”. Frontiers in Microbiology (2022).
19. Debarbieux L and Ricard JD. “Phages thérapeutiques: perspectives et défis”. Medical Sciences (Paris) (2022).
20. Dąbrowska K. “Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review”. Medicinal Research Reviews5 (2019): 2000-2025.
21. Fauconnier A. “Regulation of phage therapy in Europe and worldwide”. Viruses 11 (2019): 343.